Overview
- Product nameAnti-CHMP2A antibodySee all CHMP2A primary antibodies ...
- DescriptionRabbit polyclonal to CHMP2A
- Tested applicationsWB more details
- Species reactivityReacts with: Human
- Immunogen
Synthetic peptide corresponding to a region within C terminal amino acids 169-218 (DELGLSLTDE LSNLPSTGGS LSVAAGGKKA EAAASALADA DADLEERLKN) of Human CHMP2A (NP_055268).
- Positive control293T cell lysate.
Properties
- FormLiquid
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
- Storage bufferConstituents: 97% PBS, 2% Sucrose
-
Concentration information loading... - PurityImmunogen affinity purified
- Clonality Polyclonal
- IsotypeIgG
- Research Areas
Applications
Our Abpromise guarantee covers the use of ab118729 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| Application | Notes |
|---|---|
| WB | WB: Use a concentration of 1 µg/ml. Predicted molecular weight: 25 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T. |
Target
- FunctionProbable core component of the endosomal sorting required for transport complex III (ESCRT-III) which is involved in multivesicular bodies (MVBs) formation and sorting of endosomal cargo proteins into MVBs. MVBs contain intraluminal vesicles (ILVs) that are generated by invagination and scission from the limiting membrane of the endosome and mostly are delivered to lysosomes enabling degradation of membrane proteins, such as stimulated growth factor receptors, lysosomal enzymes and lipids. The MVB pathway appears to require the sequential function of ESCRT-O, -I,-II and -III complexes. ESCRT-III proteins mostly dissociate from the invaginating membrane before the ILV is released. The ESCRT machinery also functions in topologically equivalent membrane fission events, such as the terminal stages of cytokinesis and the budding of enveloped viruses (HIV-1 and other lentiviruses). ESCRT-III proteins are believed to mediate the necessary vesicle extrusion and/or membrane fission activities, possibly in conjunction with the AAA ATPase VPS4. Involved in HIV-1 p6- and p9-dependent virus release.
- Sequence similaritiesBelongs to the SNF7 family.
- DomainThe acidic C-terminus and the basic N-termminus are thought to render the protein in a closed, soluble and inactive conformation through an autoinhibitory intramolecular interaction. The open and active conformation, which enables membrane binding and oligomerization, is achieved by interaction with other cellular binding partners, probably including other ESCRT components.
- Cellular localizationLate endosome membrane. Localizes to the midbody of dividing cells. Localized in two distinct rings on either side of the Fleming body.
-
Database links
- Entrez Gene: 27243 Human
- Omim: 610893 Human
- SwissProt: O43633 Human
- Unigene: 12107 Human
Target information above from: UniProt accession
O43633
The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010)
.
-
Alternative names
- BC2 antibodyCharged multivesicular body protein 2a antibodyCHM2A_HUMAN antibody
- CHMP2 antibodyCHMP2a antibodyChromatin modifying protein 2a antibodyChromatin-modifying protein 2a antibodyhVps2 1 antibodyhVps2-1 antibodyputative breast adenocarcinoma marker antibodyPutative breast adenocarcinoma marker BC-2 antibodyPutative breast adenocarcinoma marker BC2 antibodyVacuolar protein sorting associated protein 2 1 antibodyVacuolar protein sorting-associated protein 2-1 antibodyVps2 1 antibodyVPS2 antibodyVps2-1 antibodyVPS2A antibody
see all
Anti-CHMP2A antibody images
-
Anti-CHMP2A antibody (ab118729) at 1 µg/ml + 293T cell lysate at 10 µg
Predicted band size : 25 kDa
References for Anti-CHMP2A antibody (ab118729)
ab118729 has not yet been referenced specifically in any publications.


